Search results for "chronic"

showing 10 items of 3309 documents

Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators

2021

Both the initiation and the resolution of inflammatory responses are governed by the sequential activation, migration, and control/suppression of immune cells at the site of injury. Bioactive lipids play a major role in the fine-tuning of this dynamic process in a timely manner. During inflammation and its resolution, polymorphonuclear cells (PMNs) and macrophages switch from producing pro-inflammatory prostaglandins and leukotrienes to specialized pro-resolving lipid mediators (SPMs), namely, lipoxins, resolvins, protectins, and maresins, which are operative at the local level to limit further inflammation and tissue injury and restore homeostasis. Accumulating evidences expand now the rol…

chronic inflammationT cellT-LymphocytesImmunologyInflammationReviewBiologymedicine.disease_causeT-Lymphocytes RegulatoryAutoimmunity03 medical and health sciencesImmunomodulating Agents0302 clinical medicineImmune systemmedicineHumansImmunology and Allergy030304 developmental biology0303 health sciencestherapyEffectorautoimmunityresolutionT cellLipid signalingadaptive immunityRC581-607Acquired immune systemCellular Reprogramming3. Good healthLipoxinsmedicine.anatomical_structureEicosapentaenoic AcidImmunologyspecialized pro-resolving lipid mediators (SPMs)Eicosanoidsmedicine.symptomImmunologic diseases. AllergyInflammation MediatorsHomeostasis030215 immunologyFrontiers in Immunology
researchProduct

Dataset relative to article "Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy"

2021

This record contains data related to article “Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy". Abstract For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There…

chronic inflammatory demyelinating polyradiculoneuropathySensitivitynervous systemAnti-MAG polyneuropathyELISASpecificity.
researchProduct

Dataset related to article "Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiag…

2021

This record contains data related to article “Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?" Abstract Background and purpose: The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. Methods: The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed. Results: In all, 535 p…

chronic inflammatory demyelinating polyradiculoneuropathydiagnostic criteriaelectrophysiology
researchProduct

Pericardial thickening in chronic kidney disease: what meaning?

2010

chronic kidney disease pericardial thickening
researchProduct

Impact of diabetes on left ventricular geometry in hypertensive patients with chronic kidney disease

2009

chronic kidney disease.Left ventricular hypertrophyDiabete
researchProduct

Compliance with the clinical practice guidelines for the management of hepatitis B and C virus-related chronic liver disease: a survey based on hospi…

2013

chronic liver disease clinical practice guidelines antiviral therapy ultrasound screening compliance
researchProduct

Molecular profiling of chronic myelogenous leukemia cell lines: identification of new molecular markers for the characterization of leukemia phenotype

2009

chronic myelogenous leukemiaProteome profiling
researchProduct

Chronic myeloid leukemia as second malignancy; restrospective multicentric study

2009

chronic myeloid leukemia second malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

2009

chronic myeloid leukemia secondary malignancySettore MED/15 - Malattie Del Sangue
researchProduct

THE ANTINEOPLASTIC ROLE OF STAT5 INHIBITION IN BCRABL1-POSITIVE CELLS EXPOSED TO PIMOZIDE ALONE AND IN COMBINATION WITH DASATINIB AND PONATINIB

2021

EVEN though the last decades have seen the success of the targeted treatments for BCRABL1-positive Chronic Myeloid Leukemia (CML), with the outstanding achievement of placing selected patients into the so called treatment-free remission, a minor part of these subjects face TKI resistance and/or intolerance. Resistance is a challenging point in the clinical management of CML, occurring in approximately 10–20% of CML cases, due to several mechanisms, among which point mutations of the BCR‐ABL kinase domain, BCRABL overexpression or alternative splicing, sub-efficient plasma concentration of the inhibitor and abnormal drug efflux/influx. The Signal Transducer and Activators of Transcription (S…

chronic myeloid leukemiaK562STAT5 inhibitorpimozideSTAT5Settore MED/15 - Malattie Del Sangue
researchProduct